Pipeline
Cyrus is advancing biologics for IgG mediated autoimmune disease (IdeS enzyme), Acute Respiratory Distress Syndrome (ACE2v2), Infectious Disease (CMV) metabolic disorders (IL-22) and oncology (IL-15), built and advanced using our protein design platform that combines AI, Rosetta, and large scale laboratory screening.
internal pipeline
CYR212 Next-Gen IdeS
Autoimmune
Multiple severe autoimmune diseases, such as Immune Thrombocytopenia (ITP) and warm Autoimmune Hemolytic Anemia (wAIHA) among many others, are driven by pathogenic IgG auto-antibodies.
Cyrus’ IgG protease – derived from the streptococcus bacterium – is able to rapidly deplete these auto-antibodies to provide rapid, deep and sustained relief from the major symptoms of these diseases.
Next-Gen IL-22
Autoimmune, Tissue Protection & Metabolic
IL-22 promotes tissue protection and regeneration, especially for gastrointestinal disorders and viral infections. This cytokine also appears to promote weight loss. The challenge for most IL-22 therapies in development has been the presence of an IL-22 specific binding protein (IL-22BP) that inhibits therapy. Cyrus’ IL-22 is BP-resistant as well as half-life extended.
Next-Gen IL-15
Solid & Hematologic Tumors
IL-15 activates effector T-cells (Teff) and Natural Killer (NK) cells, stimulating an immune response to tumors in the body. However, IL-15 can also trigger toxicity – such as neutropenia – at higher doses. Cyrus’ IL-15 has a larger therapeutic window via a proprietary AI-designed slow-release modification.
Partnering pipeline
ACE2.v2 ARDS Biologic
Acute Respiratory Distress Syndrome
ARDS is a major cause of mortality, especially in critical care situations. The ACE2 protein plays a key role in the Renin-Angiotensin pathway in the regulation of cardiovascular physiology and has been shown to be dysregulated in ARDS. Previous work by major Pharma firms has tested the wild-type ACE2 as a therapeutic in ARDS, but the wild-type protein has a very short half life, limiting it’s utility. Cyrus has used its protein design and glycosylation platform to extend the half life of the candidate ACE2v2, now in early IND enabling studies.
CYR212 Next-Gen IdeS
AAV-mediated Gene Therapy
The adeno-associated virus (AAV), used commonly to deliver gene therapy is often attacked by the immune system, interfering with gene delivery. IgG antibodies form the core of this attack. Cyrus’ IgG protease – derived from the streptococcus bacterium – is able to rapidly deplete these IgG antibodies, maintaining very low levels of IgG for an extended period of time, providing a significant window for the delivery and uptake of gene therapy.
hCMV Receptor Decoy
Receptor Decoy
Human Cytomegalovirus is the leading non-genetic cause of birth defects including hearing loss, but there is no current therapeutic that is safe for use during pregnancy. Cyrus is engineering a natural hCMV receptor decoy with extended half life as a novel therapeutic, now in pre-clinical studies. The natural receptor has low specificity with high off-target binding. We have used our platform to engineer a high specificity, extended half life version as our candidate, now in non-human primate studies.
IL-6 Pathway Agonist
IL-6 Pathway Agonist
Non-publicly disclosed milestone and royalty-based collaboration in IL-6.
“People would leap to join that clinical trial.”
Director of Clinical Hematology
Major Research Hospital